Is a titration interval of three weeks better supported than four weeks for mazdutide?

The case in front of me: three weeks · mazdutide.

This is asserted often enough that I assumed it was established, and then I went looking for the source.

I have searched the primary literature and found one paper that is adjacent but not on point.

Has anyone verified this independently?

The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.

Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.

Mechanically, liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.

Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.

A schedule described here is a published schedule for a licensed product and is not a recommendation.

Stepping back is a normal adjustment, not a failure.

The short version: four-weekly steps for the weekly agents, hold rather than escalate when symptoms are active, and slower is always available.

Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.

The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.

Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.

The top of the schedule is not the target. The working dose is.

Answering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.

The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.

Mechanically, holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.

The caveat is that titration decisions belong with a clinician who knows what else is on board.

Slower costs time and nothing else. The ceiling is the same.

Worth being precise here: escalating while symptomatic resets the tolerance process and is the mechanism behind most miserable titrations.

For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Four half-lives between steps, minimum. Work it out for your agent.

Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.

The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.

Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.

Hold rather than escalate while symptoms are active. Always.